Status:
COMPLETED
DNA Analysis of Blood and/or Tissue Samples From Patients With Primary Kidney Cancer Receiving Sorafenib on Clinical Trial MRC-RE05-SORCE
Lead Sponsor:
Medical Research Council
Conditions:
Kidney Cancer
Eligibility:
All Genders
18+ years
Brief Summary
RATIONALE: Studying samples of blood and/or tissue in the laboratory from patients with kidney cancer receiving sorafenib may help doctors learn more about changes that occur in DNA and identify bioma...
Detailed Description
OBJECTIVES: * Examine the relationship between tumor genotype, expression, and patient outcome. * Examine the relationship between constitutional genotype and patient outcome. OUTLINE: This is a mul...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Histologically confirmed resected renal cell carcinoma
- Clear cell or non-clear cell tumor
- Receiving sorafenib tosylate on clinical trial MRC-RE05-SORCE
- PATIENT CHARACTERISTICS:
- Not specified
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Exclusion
Key Trial Info
Start Date :
July 1 2007
Trial Type :
OBSERVATIONAL
End Date :
June 1 2012
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00900536
Start Date
July 1 2007
End Date
June 1 2012
Last Update
August 12 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Addenbrooke's Hospital
Cambridge, England, United Kingdom, CB2 2QQ